Agenus Inc. Reports Director Changes and Financial Updates
Ticker: AGEN · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1098972
Sentiment: neutral
Topics: director-change, financial-update
TL;DR
Agenus Inc. swapped a director, added a new one, and filed financial updates.
AI Summary
On August 7, 2024, AGENUS INC. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Robert L. S. Van der Laan and the election of new director Dr. David E. R. Sutherland. Additionally, the company reported on its financial condition and results of operations, though specific financial figures were not detailed in this summary.
Why It Matters
Changes in board composition and financial reporting can signal shifts in company strategy or performance, impacting investor confidence and future outlook.
Risk Assessment
Risk Level: medium — Director changes and financial condition updates can introduce uncertainty about the company's future direction and performance.
Key Players & Entities
- AGENUS INC. (company) — Registrant
- Dr. Robert L. S. Van der Laan (person) — Departing Director
- Dr. David E. R. Sutherland (person) — Newly Elected Director
- August 7, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to AGENUS INC.?
Dr. David E. R. Sutherland has been elected as a new director to AGENUS INC.
Who has departed from the board of directors at AGENUS INC.?
Dr. Robert L. S. Van der Laan has departed from the board of directors at AGENUS INC.
What is the principal executive office address for AGENUS INC.?
The principal executive office address for AGENUS INC. is 3 Forbes Road, Lexington, MA 02421.
What is the fiscal year end for AGENUS INC.?
The fiscal year end for AGENUS INC. is December 31st.
What is the SIC code for AGENUS INC.?
The Standard Industrial Classification (SIC) code for AGENUS INC. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 9.4 · Accepted 2024-08-08 16:49:59
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
Filing Documents
- d800799d8k.htm (8-K) — 30KB
- d800799dex51.htm (EX-5.1) — 5KB
- d800799dex991.htm (EX-99.1) — 44KB
- d800799dex992.htm (EX-99.2) — 11KB
- g800799g0808090034380.jpg (GRAPHIC) — 6KB
- 0001193125-24-197046.txt ( ) — 232KB
- agen-20240807.xsd (EX-101.SCH) — 3KB
- agen-20240807_lab.xml (EX-101.LAB) — 17KB
- agen-20240807_pre.xml (EX-101.PRE) — 11KB
- d800799d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement dated July 22, 2020 by and between Agenus Inc. and B. Riley FBR, Inc. Incorporated by reference to Exhibit 1.2 on Form S-3ASR filed by the Company on July 22, 2020 5.1 Opinion of Ropes & Gray LLP 23.1 Consent of Ropes & Gray LLP (included in Exhibit 5.1) 99.1 Press Release dated August 8, 2024 99.2 Press Release dated August 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 8, 2024 Agenus Inc. By: /s/ Christine M. Klaskin Christine M. Klaskin VP Finance